Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

Zusammenfassung

Das vorliegende Positionspapier (AWMF) zur Therapie der Sarkoidose der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) wurde 2023 als deutschsprachige Ergänzung und Aktualisierung der internationalen Leitlinien der European Respiratory Society (ERS) aus dem Jahre 2021 verfasst. Sie enthält 5 im Konsensusverfahren abgestimmte Empfehlungen in Form von PICO-Fragen (Patients, Intervention, Comparison, Outcomes), die im Hintergrundtext der 4 Kapitel erläutert werden: Diagnosesicherung und Monitoring der Erkrankung unter Therapie, allgemeine Therapieempfehlungen, Therapie der Hautsarkoidose, Therapie der kardialen Sarkoidose.

Abstract

The present recommendations on the therapy of sarcoidosis of the German Respiratory Society (DGP) was written in 2023 as a German-language supplement and update of the international guidelines of the European Respiratory Society (ERS) from 2021. It contains 5 PICO questions (Patients, Intervention, Comparison, Outcomes) agreed in the consensus process, which are explained in the background text of the four articles: Confirmation of diagnosis and monitoring of the disease under therapy, general therapy recommendations, therapy of cutaneous sarcoidosis, therapy of cardiac sarcoidosis.

Schlüsselwörter

Sarkoidose - Therapie - Leitlinien - Therapieempfehlungen

Keywords

sarcoidosis - guideline - therapeutic recommendations

Publication History

Article published online:
26 February 2024

• 
  Präambel

• 1 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med 1999; 160: 736-755
• 2 Crouser ED, Maier LA, Wilson KC. et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201: e26-e51
• 3 Baughman RP, Valeyre D, Korsten P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079

• 
  1 Diagnose der Erkrankung unter Therapie

• 1 Thillai M, Atkins CP, Crawshaw A. et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax 2021; 76: 4-20
• 2 Melani AS, Simona A, Armati M. et al. A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist. Pulm Ther 2021; 7: 309-324
• 3 Crouser ED, Maier LA, Wilson KC. et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201: e26-e51
• 4 Valeyre D, Prasse A, Nunes H. et al. Sarcoidosis. Lancet 2014; 383: 1155-1167

• 
  2 Allgemeine Therapieempfehlungen

• 1 James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol 2018; 11: 677-687
• 2 Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66
• 3 Baughman RP, Drent M, Kavuru M. et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802
• 4 Judson MA, Baughman RP, Costabel U. et al. Safety and efficacy of ustekinumab or golimumabin patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296-1307
• 5 Baughman RP, Valeyre D, Korsten P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079
• 6 Thillai M, Atkins CP, Crawshaw A. et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax 2021; 76: 4-20
• 7 Ertz-Archambault N, Kosiorek H, Taylor GE. et al. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 2017; 3: 936-943
• 8 Galor A, Jabs DA, Leder HA. et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115: 1826-1832
• 9 Ramiro S, Gaujoux-Viala C, Nam JL. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-535
• 10 Vorselaars ADM, Wuyts WA, Vorselaars VMM. et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013; 144: 805-812
• 11 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851
• 12 Fang C, Zhang Q, Wang N. et al. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36: 217-227
• 13 Müller-Quernheim J, Kienast K, Held M. et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122
• 14 Rossides M, Kullberg S, Di Giuseppe D. et al. Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real-world data. Respirology 2021; 26: 452-460
• 15 Götestam Skorpen C, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases 2016; 75: 795
• 16 Sepriano A, Kerschbaumer A, Smolen JS. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020; 79: 760-770
• 17 Lange E, Blizzard L, Venn A. et al. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford) 2016; 55: 1594-1600
• 18 Pagnoux C, Mahr A, Hamidou MA. et al. Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. New England Journal of Medicine 2008; 359: 2790-2803
• 19 Ardizzone S, Bollani S, Manzionna G. et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohnʼs disease: a randomised, investigator-blind study. Dig Liver Dis 2003; 35: 619-627
• 20 Patel AN, Langan SM, Batchelor JM. A randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal. Br J Dermatol 2012; 166: 701-704 discussion 4
• 21 Vorselaars AD, Crommelin HA, Deneer VH. et al. Effectiveness of infliximab in refractory FDG PET positive sarcoidosis. Eur Respir J 2015; 46: 175-185
• 22 Vorselaars AD, Verwoerd A, van Moorsel CH. et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43: 602-609 DOI: 10.1183/09031936.00055213.
• 23 Schimmelpennink MC, Vorselaars ADM, van Beek FT. et al. Efficacy and safety of infliximab biosimilar Inflectra((R)) in severe sarcoidosis. Respir Med 2018; 138S: S7-S13 DOI: 10.1016/j.rmed.2018.02.009.
• 24 Sakkat A, Cox G, Hambly N. et al. Infliximab Therapy in Refractory Sarcoidosis: A Multicenter Real-World Analysis. Resp Research 2022; 23: 54
• 25 Rossman MD, Newman LS, Baughman RP. et al. A double-blind, randomized, placebocontrolled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208
• 26 Drent M, Cremers JP, Jansen TL. et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 91-107
• 27 Baughman RP, Judson MA, Lower EE. et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32: 289-295
• 28 Stagaki E, Mountford WK, Lackland DT. et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135: 468-476
• 29 Gelfand JM, Bradshaw MJ, Stern BJ. et al. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology 2017; 89: 2092-2100
• 30 Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C. et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum 2017; 47: 288-294
• 31 Keane J, Gershon S, Wise RP. et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001; 345: 1098-1104
• 32 Schoels M, Aletaha D, Smolen JS. et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303-1308
• 33 Judson MA, Baughman RP, Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296-1307
• 34 Sweiss NJ, Noth I, Mirsaeidi M. et al. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 46-54
• 35 Minnis PA, Poland M, Keane MP. et al. Adalimumab for refractory pulmonary sarcoidosis. Ir J Med Sci 2016; 185: 969-971
• 36 Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia 2007; 13: S47-S50
• 37 Crommelin HA, van der Burg LM, Vorselaars AD. et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med 2016; 115: 72-77
• 38 Baughman RP, Lower EE, Bradley DA. et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-1067
• 39 Utz JP, Limper AH, Kalra S. et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-185
• 40 Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48
• 41 Sahoo DH, Bandyopadhyay D, Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150
• 42 Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75: 580-585
• 43 Cannon GW, Holden WL, Juhaeri J. et al. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004; 31: 1906-1911
• 44 Baltzan M, Mehta S, Kirkham TH. et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197
• 45 Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 1964; 425: 302S-308S
• 46 Drake WP, Culver DA, Baughman RP. et al. Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. Chest 2021; 159: 1902-1912
• 47 Park MK, Fontana JR, Babaali H. et al. Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 121-131
• 48 Wyser CP, van Schalkwyk EM, Alheit B. et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med 1997; 156: 1571-1576
• 49 Flaherty KR, Wells AU, Cottin V. et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381: 1718-1727
• 50 Wells AU, Flaherty KR, Brown KK. et al. INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453-460
• 51 Yusen RD, Christie JD, Edwards LB. et al. The registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2013; 32: 965-978
• 52 Fleitas Sosa DC, Gayen S, Zheng M. et al. Sarcoidosis lung transplantation waitlist mortality, a national registry database study. ERJ Open Res 2023; 9: 00738-2022
• 53 Meyer KC. Lung transplantation for pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36: 92-107

• 
  3 Therapie der Hautsarkoidose

• 1 Newman LS. Sarcoidosis. N Engl J Med 1997; 336: 1224-1234
• 2 Wilson NJ, King CM. Cutaneous sarcoidosis. Postgrad Med J 1998; 74: 649-652
• 3 Wanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med 2015; 36: 685-702
• 4 Kluger N. et al. Sarcoidosis on tattoos: a review of the literature from 1939 to 2011. Sarcoidosis VDLD 2013; 30: 86-102
• 5 Ohtsuka M. et al. Sarcoidal granuloma presenting on tattoo: a report of a Japanese female patient and a review of Japanese published work. Sarcoidosis VDLD 2016; 33: 83
• 6 Rosenbach M. Cutaneous sarcoidosis EDU-0321-2020 ERM 2022 in press.
• 7 Baughman RP. et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9: 155-161
• 8 Spiteri MA. et al. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 1985; 112: 315-322
• 9 Stagaki E. et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135: 468-476
• 10 Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007; 25: 334-340
• 11 Stagaki E, Mountford WK, Lackland DT. et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135: 468-476
• 12 Baughman RP, Judson MA, Ingledue R. et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148: 262-264
• 13 Baughman RP. et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9: 155-161
• 14 Judson MA. et al. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med 2015; 191: 786-795
• 15 Patel AS. et al. The development and validation of the Kingʼs Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013; 68: 57-65
• 16 Noe MH, Rodriguez O, Taylor L. et al. High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 136-141
• 17 Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol 2005; 30: 120-124
• 18 Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992; 72: 69-71
• 19 Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995; 131: 617-618
• 20 Callen JP. Intralesional corticosteroids. J Am Acad Dermatol 1981; 4: 149-151
• 21 Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007; 56: 69-83
• 22 Baughman RP. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079
• 23 Chang MM, Choi PCL, Ip FFC. Cutaneous sarcoidosis: a case series from a regional hospital in Hong Kong. Hong Kong J Dermatol Venereol 2012; 20: 153-161
• 24 Ungprasert P, Wetter DA, Crowson CS. et al. Epidemiology of cutaneous sarcoidosis, 1976–2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol 2016; 30: 1799-1804 DOI: 10.1111/jdv.13760.
• 25 Tong C, Zhang X, Dong J. et al. Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis. Int J Clin Exp Pathol 2014; 7: 372-377
• 26 Collin B, Rajaratnam R, Lim R. et al. A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department. Clin Exp Dermatol 2010; 35: 131-134
• 27 Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?. J Am Acad Dermatol 2006; 54: 55-60
• 28 Baughman RP, Judson MA, Lower EE. et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32: 289-295
• 29 Judson MA, Baughman RP, Costabel U. et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196
• 30 Judson MA, Baughman RP, Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296-1307
• 31 Pariser RJ, Paul J, Hirano S. et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68: 765-773
• 32 Droitcourt C, Rybojad M, Porcher R. et al. A randomized, investigator masked double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. N Engl J Med 1997; 336: 1224-1234
• 33 Baughman RP, Judson MA, Lower EE. et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32: 289-295
• 34 Baughman RP, Judson MA, Teirstein AS. et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122: 227-232
• 35 British Tuberculosis Association. Chloroquine in the treatment of sarcoidosis. Tubercle 1967; 48: 257-272
• 36 Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 1964; 425: 302S-308S
• 37 Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23: 487-489
• 38 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851
• 39 Webster GF, Razsi LK, Sanchez M. et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24: 451-454
• 40 Gedalia A, Molina JF, Ellis GS. et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997; 130: 25-29
• 41 Rajendran R, Theertham M, Salgia R. et al. Methotrexate in the treatment of cutaneous sarcoidosis. Sarcoidosis 1994; 11: S335-S338
• 42 Baughman RP, Judson MA, Ingledue R. et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148: 262-264
• 43 Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48
• 44 Vorselaars AD, Wuyts WA, Vorselaars VM. et al. Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest 2013; 144: 805-812
• 45 Hamzeh N, Voelker A, Forssen A. et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med 2014; 108: 1663-1669
• 46 Sahoo DH, Bandyopadhyay D, Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150
• 47 Drake WP, Oswald-Richter K, Richmond BW. et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol 2013; 149: 1040-1049
• 48 Drake WP, Culver DA, Baughman RP. et al. Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis. Chest 2021; 159: 1902-1912
• 49 Damsky W, Thakral D, Emeagwali N. et al. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. N Engl J Med 2018; 379: 2540-2546
• 50 Talty R. et al. Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep 2021; 16: 62-64
• 51 Kerkemeyer KL, Meah N, Sinclair RD. Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series. J Am Acad Dermatol 2021; 84: 581-583
• 52 Baughman RP, Drent M, Kavuru M. et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802
• 53 Wilson NJ, King CM. Cutaneous sarcoidosis. Postgrad Med J 1998; 74: 649-652

• 
  4 Therapie der kardialen Sarkoidose

• 1 Baughman RP, Teirstein AS, Judson MA. et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889
• 2 Patel MR, Cawley PJ, Heitner JF. et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969-1977
• 3 Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58: 1204-1211
• 4 Pizarro C, Goebel A, Dabir D. et al. Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32: 325-335
• 5 Ribeiro Neto ML, Jellis CL, Joyce E. et al. Update in cardiac sarcoidosis. Ann Am Thorac Soc 2019; 16: 1341-1350
• 6 Ise T, Hasegawa T, Morita Y. et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 2014; 100: 1165-1172
• 7 Hulten E, Agarwal V, Cahill M. et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2016; 9: e005001
• 8 Blankstein R, Osborne M, Naya M. et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-336
• 9 Yazaki Y, Isobe M, Hiroe M. et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010
• 10 Fussner LA, Karlstedt E, Hodge DO. et al. Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres. Eur J Heart Fail 2018; 20: 1713-1720
• 10 Zhou Y, Lower EE, Li H-P. et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151: 139-148
• 12 Flores RJ, Flaherty KR, Jin Z. et al. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2020; 27: 2003-2010
• 13 Kandolin R, Lehtonen J, Airaksinen J. et al. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol 2015; 116: 960-964
• 14 Sperry BW, Tamarappoo BK, Oldan JD. et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018; 11: 336-345
• 15 Joyce E, Ninaber MK, Katsanos S. et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 2015; 17: 51-62
• 16 Al-Khatib SM, Stevenson WG, Ackerman MJ. et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018; 15: e190-e252
• 17 Kazmirczak F, Chen KA, Adabag S. et al. Assessment of the 2017 AHA/ACC/HRS guideline recommendations for implantable cardioverter-defibrillator implantation in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2019; 12: e007488
• 18 Birnie DH, Sauer WH, Bogun F. et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305-1323
• 19 Costabel U, Skowasch D, Pabst S. et al. Cardiac sarcoidosis: diagnostic and therapeutic algorithms. Pneumologie 2014; 68: 124-132
• 20 Skowasch D, Gaertner F, Marx N. et al. Diagnostics and treatment of cardiac sarcoidosis – consensus paper of the German Respiratory Society (DGP) and the German Cardiac Society (DGK). Pneumologie 2020; 74: 24-34
• 21 Adhaduk M, Paudel B, Liu K. et al. The role of electrophysiology study in risk stratification of cardiac sarcoidosis patients: Meta-analysis and systemic review. Int J Cardiol 2022; 349: 55-61
• 22 Tandon P, Mosleh T, Mustafa A. et al. Utility of electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis patients with mildly impaired left ventricular function. Respir Med 2022; 191: 106712
• 23 Kobayahi Y, Sato T, Nagai T. et al. Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis. ESC Heart Fail 2021; 8: 5282-5292
• 24 Stievenart J, Le Guenno G, Ruivard M. et al. Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies. Eur Resp J 2021; 59: 2100449
• 25 Fazelpour S, Sadek MM, Nery PB. et al. Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: A systematic review. J Am Heart Assoc 2021; 10(17): e021183
• 26 Triveri MG, Spagnolo P, Birnie D. et al. Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol 2020; 76: 1878-1901
• 27 Zeppenfeld K, Tfelt-Hansen J, de Riva M. et al. 2022 ESC guidelines fort he management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 21: 3997-4126
• 28 Siontis KC, Santangeli P, Muser D. et al. Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. JAMA Cardiol 2021; 7: 175-183
• 29 Skowasch D, Ringquist S, Nickenig G. et al. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator. PLoS One 2018; 13: e0194496
• 30 Hou Y, Lower EE, Li H-P. et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151: 139-148
• 31 Slart RHJA, Glaudemans AWJM, Lancellotti P. et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol 2018; 25: 298-319
• 32 Nagai S, Yokomatsu T, Tanizawa K. et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 2014; 53: 427-433
• 33 Padala SK, Peaslee S, Sidhu MS. et al. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol 2017; 227: 565-570
• 34 Nagai T, Nagano N, Sugano Y. et al. Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis. Am J Cardiol 2016; 117: 966-971
• 35 Ise T, Hasegawa T, Morita Y. et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 2014; 100: 1165-1172
• 36 Yazaki Y, Isobe M, Hiroe M. et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010
• 37 Zhou Y, Lower EE, Li H-P. et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151: 139-148
• 38 Kandolin R, Lehtonen J, Airaksinen J. et al. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol 2015; 116: 960-964
• 39 Sperry BW, Tamarappoo BK, Oldan JD. et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018; 11: 336-345
• 40 Nagai T, Nagano N, Sugano Y. et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J 2015; 79: 1593-1600
• 41 Kato Y, Morimoto S, Uemura A. et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 133-137
• 42 Murtagh G, Laffin LJ, Beshai JF. et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016; 9: e003738
• 43 Chapelon-Abric C, Sene D, Saadoun D. et al. Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors. Arch Cardiovasc Dis 2017; 110: 456-465
• 44 Chapelon-Abric C, de Zuttere D, Duhaut P. et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine 2004; 83: 315-334
• 45 Greulich S, Deluigi CC, Gloekler S. et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013; 6: 501-511
• 46 Mohsen A, Jimenez A, Hood RE. et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow- up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol 2014; 25: 171-176
• 47 Kudoh H, Fujiwara S, Shiotani H. et al. Myocardial washout of 99mTc-tetrofosmin and response to steroid therapy in patients with cardiac sarcoidosis. Ann Nucl Med 2010; 24: 379-385
• 48 Kandolin R, Lehtonen J, Airaksinen J. et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131: 624-632
• 49 Nagano N, Nagai T, Sugano Y. et al. Association between basal thinning of interventricular septum and adverse long-term clinical outcomes in patients with cardiac sarcoidosis. Circ J 2015; 79: 1601-1608
• 50 Takaya Y, Kusano KF, Nakamura K. et al. Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement. Int J Cardiol 2014; 176: 522-525
• 51 Kato Y, Morimoto S, Uemura A. et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 133-137
• 52 Ujita N, Hiroe M, Suzuki Y. et al. A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities. Heart Vessels Suppl 1990; 5: 16-18
• 53 Hiramitsu S, Morimoto S, Uemura A. et al. National survey on status of steroid therapy for cardiac sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 210-213
• 54 Okabe T, Yakushiji T, Hiroe M. et al. Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction. ESC Heart Fail 2016; 3: 288-292
• 55 Padala SK, Peaslee S, Sidhu MS. et al. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol 2017; 227: 565-570
• 56 Nagai T, Kohsaka S, Okuda S. et al. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 2014; 146: 1064-1072
• 57 Khan NA, Donatelli CV, Tonelli AR. et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 2017; 132: 9-14
• 58 Rahaghi FF, Baughman RP, Saketkoo LA. et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev 2020; 29: 190146
• 59 Fussner LA, Karlstedt E, Hodge DO. et al. Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres. Eur J Heart Fail 2018; 20: 1713-1720
• 60 Zhou Y, Lower EE, Li H-P. et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151: 139-148
• 61 Ballul T, Borie R, Crestani B. et al. Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol 2019; 276: 208-211
• 62 Nagai S, Yokomatsu T, Tanizawa K. et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 2014; 53: 427-433
• 63 Harper LJ, McCarthy M, Neto MLR. et al. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol 2019; 124: 1630-1635
• 64 Baker MC, Sheth K, Witteles R. et al. TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Semin Arthritis Rheum 2020; 50: 546-552
• 65 Ribeiro Neto ML, Jellis CL, Joyce E. et al. Update in cardiac sarcoidosis. Ann Am Thorac Soc 2019; 16: 1341-1350
• 66 Sadek MM, Yung D, Birnie DH. et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013; 29: 1034-1041
• 67 Yazaki Y, Isobe M, Hiroe M. et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010
• 68 Zhou Y, Lower EE, Li H-P. et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151: 139-148
• 69 Padala SK, Peaslee S, Sidhu MS. et al. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol 2017; 227: 565-570
• 70 Baughman RP, Scholand MB, Rahaghi FF. Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev 2020; 29: 190145
• 71 Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012; 141: 154-162
• 72 Slart RHJA, Glaudemans AWJM, Lancellotti P. et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol 2018; 25: 298-319
• 73 Ha FJ, Agarwal S, Tweed K. et al. Imaging in suspected cardiac sarcoidosis: a diagnostic challenge. Curr Cardiol Rev 2020; 16: 90-97